Esperance Pharmaceuticals Brings Series A To $14 Million

Esperance Pharmaceuticals Inc. has added about $5 million in new funding to bring its Series A round to just under $14 million, VCE Capital Managing Partner Ross Barrett said.
MORE ON THIS TOPIC